Literature DB >> 1730683

Ligand-independent internalization and recycling of the insulin receptor. Effects of chronic treatment of 3T3-C2 fibroblasts with insulin and dexamethasone.

V P Knutson1.   

Abstract

Upon binding insulin at the plasma membrane, the insulin receptor internalizes into the endosomal compartment of the cell with a half-time of approximately 10 min. Our earlier work demonstrated that receptor inactivation (loss of insulin binding capacity) is a regulated process. Long term treatment of cultured cells with insulin or the glucocorticoid dexamethasone increases or decreases, respectively, the rate constant for insulin receptor inactivation (Knutson, V. P., Ronnett, G. V., and Lane, M. D. (1982) Proc. Natl. Acad. Sci. U.S.A. 79, 2822-2826). In these studies, monolayer cultures of 3T3-C2 fibroblasts were chronically treated with insulin or dexamethasone. Subsequently, the surface receptors were labeled with the photoactivatable cross-linking agent 125I-labeled 2-(p-azidosalicylamido)ethyl-1,3'- dithiopropionate -insulin. Following equilibration of the radiolabeled receptor between the plasma membrane and internal pools, the steady-state rate constant for receptor recycling was determined by quantitating the rate at which internal radiolabeled receptor was inserted into the plasma membrane. The steady-state rate constant for this recycling process was the same in control, insulin-treated, or steroid-treated cells (t1/2 = 2h). In contrast, the rate constant for receptor internalization was regulated; the half-times were 10 h for control cells, 5 h for insulin-treated cells, and 19 h for dexamethasone-treated cells. These changes in rate constants for internalization and inactivation lead to changes in the relative numbers of receptor molecules undergoing recycling versus inactivation. Therefore, whereas the recycling of the insulin receptor is not a regulated process, the internalization of surface receptor in the absence of bound ligand is a metabolically controlled step in receptor processing.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1730683

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  5 in total

1.  Guiding dose selection of monoclonal antibodies using a new parameter (AFTIR) for characterizing ligand binding systems.

Authors:  Sameed Ahmed; Miandra Ellis; Hongshan Li; Luca Pallucchini; Andrew M Stein
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-04-29       Impact factor: 2.745

2.  Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients.

Authors:  T Niwa; T Katsuzaki; S Miyazaki; T Miyazaki; Y Ishizaki; F Hayase; N Tatemichi; Y Takei
Journal:  J Clin Invest       Date:  1997-03-15       Impact factor: 14.808

3.  Ligand-dependent and -independent transforming growth factor-beta receptor recycling regulated by clathrin-mediated endocytosis and Rab11.

Authors:  Hugh Mitchell; Amit Choudhury; Richard E Pagano; Edward B Leof
Journal:  Mol Biol Cell       Date:  2004-06-30       Impact factor: 4.138

4.  Amino acid starvation-induced LDLR trafficking accelerates lipoprotein endocytosis and LDL clearance.

Authors:  Ye Chen; Xiao Wu; Jing Zhang; Guopin Pan; Xiaoyun Wang; Xiaosun Guo; Jianli Wang; Xiaopei Cui; Haiqing Gao; Mei Cheng; Jingwen Yang; Cheng Zhang; Fan Jiang
Journal:  EMBO Rep       Date:  2022-01-07       Impact factor: 8.807

5.  Insulin and insulin like growth factor II endocytosis and signaling via insulin receptor B.

Authors:  Jimena Giudice; Lucia Soledad Barcos; Francisco F Guaimas; Alberto Penas-Steinhardt; Luciana Giordano; Elizabeth A Jares-Erijman; Federico Coluccio Leskow
Journal:  Cell Commun Signal       Date:  2013-03-11       Impact factor: 5.712

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.